BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tegtociclib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tegtociclib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04553133-11278@assetmemo.bio
DTSTAMP:20261121T004532Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tegtociclib: Phase 2 readout est. (NCT04553133)
DESCRIPTION:Tegtociclib\, phase 2\, Breast Cancer.\nStudy: PF-07104091 as a
  Single Agent and in Combination Therapy\nEstimated primary completion: 31
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tegto
 ciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04553133
URL:https://assetmemo.bio/drug/tegtociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05262400-11278@assetmemo.bio
DTSTAMP:20261121T004532Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Tegtociclib: Phase 1/2 readout est. (NCT05262400)
DESCRIPTION:Tegtociclib\, phase 1/2\, Breast Cancer.\nStudy: A Study to Lea
 rn About the Study Medicine (Called PF-07220060 in Combination With PF-071
 04091) In Participants With Breast Cancer and Solid Tumors\nEstimated prim
 ary completion: 26 February 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tegtociclib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05262400
URL:https://assetmemo.bio/drug/tegtociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
